WILMETTE, Ill., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced that its abstract on the long-term neurological benefits of ALXN1840 (tiomolybdate choline) in Wilson disease patients has been selected for both oral and poster presentations at the 150th American Neurological Association (ANA) Annual Meeting, to ...

Core Viewpoint - Monopar Therapeutics Inc. has announced that data on the long-term efficacy and safety of its drug candidate ALXN1840 for Wilson disease will be presented at the EASL International Liver Congress 2025, highlighting the significance of this research in the hepatology field [1][2]. Group 1: Presentation Details - The late-breaker poster presentation will focus on "Sustained long-term clinical improvement in Wilson disease patients on tiomolybdate choline" [3]. - The presentation is scheduled for May 7, 2025, at 8:30 a.m. CET, and will be led by Dr. Karl Heinz Weiss [3]. - The poster will be available online on the company's website on the same day [3]. Group 2: Company Overview - Monopar Therapeutics is a clinical-stage biotechnology company with a focus on developing innovative treatments, including ALXN1840 for Wilson disease and various radiopharmaceutical programs for advanced cancers [4].